Ovarian Cancer Prevention Vaccine

“Scientists at the University of Oxford are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.

In this study, the Cancer Research UK-funded scientists will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.

If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.”

Read more on Oxford researchers secure funding for world’s first ovarian cancer prevention vaccine via University of Oxford.

HPV Vaccination

“Canada’s federal vaccine advisory body is now recommending a single dose of the HPV vaccine for children and youth, bringing the country in line with multiple others that have already reduced the number of required doses for young people.

The new guidance, out Wednesday from the National Committee on Immunization (NACI), strongly recommends that individuals nine to 20 years of age should receive one dose of the vaccine for human papillomavirus, instead of two or three.

Research over the last decade has shown that one dose of this “highly effective vaccine” can provide comparable protection against HPV infection and disease among female individuals in that age group, NACI noted. 

The advisory body still calls for two doses of the HPV vaccine for Canadians aged 21 to 26, along with a three-dose schedule for people who are immunocompromised or living with HIV.”

Read more on Canada’s vaccine advisers now recommend 1 dose of HPV shot for younger groups via CBC News.